Anteris Technologies Global (ASX:AVR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Anteris Technologies Global (ASX:AVR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
German Regulatory Clearance
Notification regarding unquoted securities - AVR
Statement of CDIs on issue - AVR
Notification of cessation of securities - AVR
Notification regarding unquoted securities - AVR
Entry into a Material Definitive Agreement
Compensatory Arrangements of Certain Officers
Appointment of Chief Financial Officer
Statement of CDIs on issue - AVR
Change of Director's Interest Notice
Notification regarding unquoted securities - AVR
Application for quotation of securities - AVR
Results for the Second Quarter of 2026
Anteris Technologies Advances PARADIGM Trial with U.S. Medicare Reimbursement and Board Expansion in Q2 2026
Quarterly Results Announcement and SEC Form 10-Q
Anteris Technologies reports Q2 2026 results with $1.5M revenue, $51.7M loss, advances DurAVR® clinical trial, raises $320M capital
Statement of CDIs on issue - AVR
Court Orders Granted
Notification of cessation of securities - AVR
Application for quotation of securities - AVR
Cleansing Notice
Cleansing Notice
Cleansing Notice Update
Trading Halt
Pause in Trading